Fortress Biotech (FBIO) to Release Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) is projected to release its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect Fortress Biotech to post earnings of $0.11 per share and revenue of $26.17 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Fortress Biotech Stock Down 4.2%

Shares of Fortress Biotech stock opened at $2.76 on Friday. The company has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $3.20. The stock has a market capitalization of $85.67 million, a PE ratio of -15.33 and a beta of 1.38. Fortress Biotech has a 52-week low of $1.33 and a 52-week high of $4.53. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.97 and a current ratio of 2.19.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in shares of Fortress Biotech by 98.8% during the 4th quarter. Renaissance Technologies LLC now owns 81,100 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 40,300 shares during the period. Bridgeway Capital Management LLC purchased a new stake in Fortress Biotech in the 4th quarter worth $667,000. Geode Capital Management LLC raised its holdings in Fortress Biotech by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 262,492 shares of the biopharmaceutical company’s stock valued at $961,000 after acquiring an additional 18,071 shares during the period. Bank of America Corp DE raised its holdings in Fortress Biotech by 923.3% during the third quarter. Bank of America Corp DE now owns 7,122 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 6,426 shares during the period. Finally, Opaleye Management Inc. purchased a new position in shares of Fortress Biotech in the fourth quarter valued at about $3,989,000. 96.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on FBIO. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Fortress Biotech in a research report on Monday, February 23rd. Zacks Research cut shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Fortress Biotech in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Fortress Biotech has an average rating of “Hold” and an average target price of $17.00.

Fortress Biotech Company Profile

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.